Key result
Elevated asymmetrical dimethylarginine (ADMA) levels are observed in pregnancies complicated by preeclampsia before clinical symptoms develop, suggesting a role in its pathogenesis.
Why the study?
What is the role of endogenous inhibitors of nitric oxide, specifically ADMA, in the pathogenesis of preeclampsia?
What is the role of endogenous inhibitors of nitric oxide, specifically ADMA, in the pathogenesis of preeclampsia?
This review highlights that elevated ADMA levels precede clinical symptoms of preeclampsia, suggesting it plays a key role in the disease's pathogenesis.
May inform early preeclampsia risk assessment; leaves open causal role and therapeutic targeting pending prospective trials.
Nitric oxide (NO) is a potent vasodilator. NO is synthesized by NO synthases (NOS) and NOS are inhibited by asymmetrical dimethylarginine (ADMA). ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH) and excreted in the kidneys. Lower ADMA levels in pregnant women compared to non-pregnant controls suggest that ADMA has a role in vascular dilatation and blood pressure changes. Several studies show an increase in ADMA levels in pregnancies complicated with preeclampsia. Elevated ADMA levels in preeclampsia are seen before clinical symptoms have developed; these findings suggest that ADMA has a role in the pathogenesis of preeclampsia.
No takes yet. Share an insight, caveat, or question.
Slaghekke et al. (2006) conducted a review in Preeclampsia. Asymmetrical dimethylarginine (ADMA) was evaluated. Elevated asymmetrical dimethylarginine (ADMA) levels are observed in pregnancies complicated by preeclampsia before clinical symptoms develop, suggesting a role in its pathogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: